⌘+K

Equity Story

Near term

6-12 MONTHS

EQL Pharma offers exposure to the generic pharmaceuticals market, focusing on niche areas with high barriers to entry. The company specialises in producing and marketing generic drugs, with a strong emphasis on high-quality, affordable medications across different therapeutic areas. It benefits from long-term trends towards cost containment and an ageing population, which support demand for generic drugs. The company’s strategic priorities include expanding its product portfolio and geographical footprint, and pursuing selective acquisitions to enhance its market position. We see the key attractions in EQL Pharma’s case as its strong regulatory expertise, focus on operational efficiency and potential for growth through international expansion and strategic partnerships.

Long term

6+ YEARS

Grand View Research forecasts steady growth in the generic pharmaceuticals market, with an expected annual sales growth rate of 8% through 2030, largely driven by a continuous stream of patent expirations. EQL Pharma targets high-value niche segments, where it can leverage its regulatory expertise and specialised organisation. We argue that the company’s focus on operational excellence and quality strengthens its competitive edge. Its opportunistic but selective M&A approach is poised to accelerate growth, in our view, enabling the company to consolidate its position in select therapeutic areas. Combine this with its ability to drive synergies across its portfolio, and we see strong potential for margin expansion and enhanced long-term profitability.

Key risks

  • Vulnerability to price pressure in the generic pharmaceuticals market, particularly from cost-containment measures or regulatory changes.

  • Execution risk in its acquisition strategy, as failure to create value from acquisitions could hinder growth prospects.

  • Dependence on third-party suppliers exposes EQL to potential delays or disruptions if suppliers fail to meet performance requirements.

  • Stronger-than-expected market share gains driven by successful product launches, faster uptake, or competitor shortages.

  • Successful integration and value creation from recent and future acquisitions, leading to faster earnings growth than anticipated.

Fair value range

Price

Fair range high value

Fair range low value

FV high (peers): applies our base multiple (18x), corresponding to no premium or discount, to our 2027/28e EBIT.FV low (peers): applies a 30% discount to our base multiple (18x) to our 2027/28e EBIT.

Valuation and methodology

We value EQL using a relative valuation approach, benchmarking it against a peer group of companies with exposure to generics, as well as a broader group of established, fast-growing companies within off-patent pharmaceuticals. Our valuation implies c13–18x EV/EBIT 2027/28e, reflecting a 0–30% discount to our base multiple (18x), which we believe is justified despite near-term uncertainty given EQL’s high-growth profile over the medium-to-longer term and superior margin potential.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB